Protocol VX20 -445-111, Version  3.0 Page 3 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  2 PROTOCOL SYNOPSIS  
Title  A Phase 3 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of 
Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis 
Subjects 2 Through 5  Years of Age  
  
Brief Title  Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5  Years  
  
Clinical Phase and 
Clinical Study Type  Phase  3, safety, tolerability, and pharmacokinetics (PK)  
  
Objectives  Part  A 
Primary Objectives  
• To evaluate the PK of elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor 
(IVA) when dosed in triple combination (TC)  
• To evaluate the safety and tolerability of ELX/TEZ/IVA  
Part  B 
Primary Objective  
To evaluate the safety and tolerability of ELX/TEZ/IVA  
Secondary Objectives  
• To evaluate the PK of ELX, TEZ, and IVA  
• To evaluate the pharmacodynamics (PD) of ELX/TEZ/IVA  
• To evaluate the efficacy of ELX/TEZ/IVA  
  
Endpoints  Part  A 
Primary Endpoints  
• PK parameters of ELX, TEZ, IVA, and relevant metabolites  
• Safety  and tolerability assessments as determined by [CONTACT_20721] (AEs), 
clinical laboratory values, standard [ADDRESS_307602] 12 -lead ECGs, vital signs, and pulse oximetry  
Secondary Endpoints  
• PK parameters of ELX, TEZ, IVA, and relevant metabolites  
• Absolute change in sweat chloride (SwCl) from baseline through Week  24 
• Absolute change in lung clearance index (LCI) 25 from baseline through 
Week  24 

Protocol VX20 -445-111, Version  3.0 Page 4 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  Number of Subjects  Part  A 
Approximately 14  subjects with F/F  or F/MF genotypes are planned for 
enrollment. Subjects who participate in Part  A may participate in Part  B. 
Part  B 
Approximately [ADDRESS_307603] 30  subjects with 
F/MF genotypes and at least 15  subjects with F/F genotypes a re targeted for 
enrollment. At least 25  subjects should be between 2 and 3  years of age 
(inclusive).  
  
Study Population  Part A  
Male and female CF subjects 2 through 5  years of age (inclusive) with F/MF or 
F/F genotypes. Subjects must weigh ≥14  kg at Day  1.  
Part B  
Male and female CF subjects 2 through 5 years of age (inclusive) who have at 
least 1 F508del  mutation in the CFTR  gene or an ELX/TEZ/IVA -responsive 
CFTR mutation . Subjects must weigh ≥10  kg at the Screening Visit . 
  
Investigational Drug  Active substance: ELX (VX -445)/TEZ (VX -661)/IVA (VX -770) 
Activity:  CFTR correctors (ELX and TEZ) and potentiator (IVA)  
Strength and route of administration:  
• Parts  A and B:  100 mg ELX/50  mg TEZ/75  mg IVA FDC granules  for oral 
admi nistration AND 75 mg IVA granules for oral administration  
• Part  B Only:  80 mg ELX/40  mg TEZ/60  mg IVA FDC granules for oral 
administration AND  59.5 mg IVA granules for oral administration  
  
Study Duration  Part  A 
Excluding the Screening Period, subjects will participate in the study for up to 
6 weeks (±  7 days)  
Part  B 
Excluding the Screening Period, subjects will participate in the study for up to 
28 weeks (±  7 days)  
  
Study Design  This is a Phase  3, 2-part (Parts  A and B), multicenter study evaluating the safety, 
tolerability, PK, PD, and efficacy of ELX/TEZ/IVA in CF subjects 2 through 
5 years of age (inclusive).  
Part  A 
A schematic of the study design for Part  A is provided below. Approximately 
14 subjects (F/F or F/MF genotypes) will be enrolled. Duri ng the Treatment 
Period, subjects will be administered ELX/TEZ/IVA for approximately [ADDRESS_307604] Weight at Day  1 ELX Dose  TEZ Dose  IVA Dose  
Part  A    
≥14 kg only  100 mg qd  50 mg qd  75 mg q12h  
Part  B    
≥14 kg 100 mg qd  50 mg qd  75 mg q12h  
≥10 kg to  <14 kg 80 mg qd  40 mg qd  60 mg qAM  
59.5 mg qPM  
ELX: elexacaftor; IVA: ivacaftor; qAM: once every morning; qd: once daily; q12h: 
every 12  hours; qPM: once every evening; TEZ: tezacaftor  
 
  
Assessments  Parts  A and B  
PK Assessments:  
PK parameters of ELX,  TEZ, IVA, and relevant metabolites  
Safety Assessments:  
AEs, clinical laboratory assessments (serum chemistry, hematology, coagulation, 
and urinalysis), standard 12 -lead ECGs, vital signs, pulse oximetry, 
ophthalmologic examinations, and physical examinations (PEs)  
Part B  
PD Assessment:  
SwCl  
Efficacy Assessments:  
Multiple -breath washout (MBW; subjects ≥3  years of age at screening of Part  B), 
  
Statistical Analyses  Data from Part  A and Part B will be analyzed separately.  
Part  A 
Approximately [ADDRESS_307605] 80% power to target a 95% CI 
within 60% and 140% of the geometric mean estimate of clearance for ELX and 
M23 -445. 
Part  B 
Approximately 70 subjects will be enrolled. With 56  subjects expected to 
complete Part  B, there is a >90% chance of observing an AE in at least [ADDRESS_307606] if 
the true incidence rate is 5%, and a >95% ch ance of observing an AE in at least 
[ADDRESS_307607] if the true incidence rate is 10%.  
For the primary endpoint, summary statistics will be provided for 
treatment -emergent AEs, clinical laboratory assessments, standard 12 -lead ECGs, 
vital signs, and pulse oximet ry. 
  

Protocol VX20 -445-111, Version  3.0 Page 7 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  DMC Reviews  An external data monitoring committee (DMC) will conduct periodic safety 
review(s) of study data as outlined in the DMC charter.  
Protocol VX20 -445-111, Version  3.0 Page 8 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  3 SCHEDULE OF ASSESSME NTS 
Schedules of assessments are shown in Table  3-1 (Part  A Screening Period), Table  3-2 (Part  A 
Treatment Period and Safety Follow -up Visit), Table  3-3 (Part  B Screening Period), and 
Table  3-4 (Part  B Treatment Period and Safety Follow -up Visit).  
Table  3-1 Study VX20 -445-111, Part A Screening Period  
Event/Assessment  Screening Visit  
Day -28 to Day  -1 Comments  
Informed consent (and assent)  X  
Demographics  X Section  11.[ADDRESS_307608] (Section  11.5.5 ) 
Full physical examination  X Section  11.5.3  
Weight  X Measured with shoes off (Section  11.4.3 ) 
Vital signs and pulse oximetry  X Performed after the subject has been at rest 
for at least  5 minutes (Section  11.5.3 ) 
Standard [ADDRESS_307609] heart rate (HR), such as blood 
draws, and in the supi[INVESTIGATOR_252850] 5  minutes 
(Section  11.5.4 ) 
CF genotype (all subjects)  X If the CFTR  genotype result is not received 
before the first dose of study drug, a previous 
CFTR  genotype laboratory report may be used 
to establish eligibility (Section  8.1). Subjects 
who have been enrolled whose screening 
genotype does not c onfirm study eligibility 
must be discontinued from the study 
(Section  9.9). 
Serum chemistry  X 
Section  11.5.2  Hematology  X 
Coagulation  X 
Urinalysis  X 
Medications review  X Information regarding medications taken 
within 56  days before the Screening Visit will 
be collected (Section  9.5) 
Adverse events  Continuous, From Signing of ICF 
through Completion of Study 
Participation  Section  13.1; completion of study 
participation is defined in Section  9.1.6 . 
AE: adverse event; CFTR : cystic fibrosis transmembrane conductance regulator gene; ECG: electrocardiogram; HR: heart 
rate; ICF: informed consent form; SAE: serious adverse event  
 

Protocol VX20 -445-111, Version  3.0 Page 11 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  Table  3-3 Study VX20 -445-111, Part B Screening Period  
Event/Assessment  Screening Visit  
Day -28 to Day  -1 Comments  
Informed consent (and assent)  X  
Demographics  X Section  11.[ADDRESS_307610] 
(Section  11.5.5 ) 
Full physical examination  X Section  11.5.3  
Weight  X Measured with shoes  off (Section  11.4.3 ) 
Vital signs and pulse oximetry  X Performed after the subject has been at rest for at least  
5 minutes (Section  11.5.3 ) 
Standard [ADDRESS_307611] 
heart rate (HR), such as blood draws, and in the supi[INVESTIGATOR_252851] 
5 minutes (Section  11.5.4 ) 
Multiple -breath washout  X Performed in multiple replicates pre- or post -
bronchodilator  in subjects 3 years of age at screening 
(Section  11.4.2 ). 
Sweat chloride  X Section  11.4.1  
CF genotype (all subjects)  X If the CFTR  genotype result is not received before the first 
dose of study drug, a previous CFTR  genotype laboratory 
report may be used to establish eligibility (Section  8.1). 
This assessment does not need to be repeated for 
confirmed subjects in Part A who wish to participate in 
Part B. Subjects who have been enrolled whose screening 
genotype does not confirm study elig ibility must be 
discontinued from the study (Section  9.9). If a subject 
weighs <11 kg at the Screening Visit and requires an 
additional blood sample for a deletion/duplication assay, 
this second tube should be drawn at the Day [ADDRESS_307612] dose of study drug 
(Section  11.5.2 ). 
Hematology  X A single set of pre-dose hematology and coagulation 
assessments will be obtained from a  blood draw taken up 
to [ADDRESS_307613] dose of study drug 
(Section 11.5.2 ). Coagulation  X 
Urinalysis  X Section 11.5.2  
Medications review  X Information regarding medications taken within 56  days 
before the Screening Visit will be collected (Section  9.5) 
Adverse events  Continuous, From 
Signing of ICF through 
Completion of Study 
Participation  Section  13.1; completion of study participation is defined 
in Section  9.1.6 . 
AE: adverse event; CFTR: cystic fibrosis transmembrane conductance regulator gene; ECG: electrocardiogram; HR: heart 
rate; ICF: informed consent form; SAE: serious adverse event  
 

Protocol VX20 -445-111, Version  3.[ADDRESS_307614] of Abbreviations ................................ ................................ ................................ ................  23 
5 Introduction ................................ ................................ ................................ ..........................  26 
5.1 Background  ................................ ................................ ................................ .....................  26 
5.2 Study Rational e ................................ ................................ ................................ ..............  26 
6 Study Objectives  ................................ ................................ ................................ ..................  27 
6.1 Primary Objectives  ................................ ................................ ................................ .........  27 
6.2 Secondary Objectives  ................................ ................................ ................................ ..... 27 
7 Study Endpoints  ................................ ................................ ................................ ...................  27 
7.1 Primary Endpoints  ................................ ................................ ................................ ..........  27 
7.2 Secondary Endpoints  ................................ ................................ ................................ ...... 27 
  
8 Study Population  ................................ ................................ ................................ ..................  28 
8.1 Inclusion Criteria  ................................ ................................ ................................ ............  28 
8.2 Exclus ion Criteria  ................................ ................................ ................................ ...........  29 
9 Study Implementation  ................................ ................................ ................................ .........  30 
9.1 Study Design  ................................ ................................ ................................ ..................  30 
9.1.1  Screening  ................................ ................................ ................................ ................  32 
[IP_ADDRESS]  Repetition of Screening Assessments  ................................ ..............................  32 
[IP_ADDRESS]  Rescreening  ................................ ................................ ................................ ...... 33 
[IP_ADDRESS]  Extension of Screening Period Window  ................................ ..........................  [ADDRESS_307615] and Disease Characteristics  ................................ ................................ ...............  43 
11.2  Pharmacokinetics  ................................ ................................ ................................ ............  44 
11.2.1  Blood Sampling  ................................ ................................ ................................ ...... 44 
11.2.2  Processing and Handling of Pharmacokinetic Samples  ................................ .........  44 
11.2.3  Bioanalysis ................................ ................................ ................................ ..............  44 
11.4  Efficacy and Pharmacodynamics (Part  B Only)  ................................ .............................  45 
11.4.1  Sweat Chloride  ................................ ................................ ................................ ....... 45 
11.4.2  Multiple -breath Washout  ................................ ................................ ........................  45 
11.5  Safety  ................................ ................................ ................................ ..............................  48 
11.5.1  Adverse Events  ................................ ................................ ................................ ....... 48 
11.5.2  Clini cal Laboratory Assessments  ................................ ................................ ...........  48 
11.5.3  Physical Examinations and Vital Signs  ................................ ................................ .. 49 
11.5.4  Electrocardiograms  ................................ ................................ ................................ . 50 
11.5.5  Ophthalmologic Examination  ................................ ................................ .................  50 
11.5.6  Contraception and Pregnancy  ................................ ................................ .................  51 
12 Statistical Analysis  ................................ ................................ ................................ ...............  51 
12.1  Sample Size and Power  ................................ ................................ ................................ .. 51 
12.2  Analysis Sets  ................................ ................................ ................................ ..................  52 
12.3  Statistical Analysis  ................................ ................................ ................................ .........  52 
12.3.1  General Considerations  ................................ ................................ ...........................  52 
12.3.2  Background Characteristics  ................................ ................................ ....................  53 
12.3.3  Efficacy and Pharmacodynamic Analysis  ................................ ..............................  53 
[IP_ADDRESS]  Analysis of Primary Efficacy Endpoints  ................................ ..........................  53 

Protocol VX20 -445-111, Version  3.0 Page 20 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  [IP_ADDRESS]  Analysis of Secondary Efficacy and Pharmacodynamic Endpoints  ................  53 
[IP_ADDRESS]  Multiplicity Adjustment  ................................ ................................ ...................  53 
12.3.4  Safety Analysis  ................................ ................................ ................................ ....... 54 
[IP_ADDRESS]  Adverse Events ................................ ................................ ................................ . 54 
[IP_ADDRESS]  Clinical Laboratory Assessments  ................................ ................................ ..... 55 
[IP_ADDRESS]  Electrocardiogram  ................................ ................................ ............................  55 
[IP_ADDRESS]  Vital Signs  ................................ ................................ ................................ ........  55 
[IP_ADDRESS]  Pulse Oximetry  ................................ ................................ ................................ . 56 
[IP_ADDRESS]  Ophthalmologic Examinations  ................................ ................................ .........  56 
[IP_ADDRESS]  Physical Examination  ................................ ................................ .......................  56 
12.4  Interim Analysis  ................................ ................................ ................................ .............  56 
12.5  Data Monitoring Committee Analysis  ................................ ................................ ............  56 
12.6  Clinical Pharmacology Analysis  ................................ ................................ ....................  56 
12.6.1  Pharmacokinetic Analysis  ................................ ................................ ......................  56 
12.6.2  Pharmacokinetic/Pharmacodynamic Analyses  ................................ .......................  56 
13 Procedural, Ethical, Regulatory, and Administrative Considerations  ...........................  57 
13.1  Adverse Event and Serious Adverse Event Documentation, Severity Grading, and 
Reporting  ................................ ................................ ................................ ........................  57 
13.1.1  Adverse Events  ................................ ................................ ................................ ....... 57 
[IP_ADDRESS]  Definition of an Adverse Event ................................ ................................ ........  57 
[IP_ADDRESS]  Clinically Significant Assessments  ................................ ................................ .. 57 
[IP_ADDRESS]  Documentation of Adverse Events ................................ ................................ ... 57 
[IP_ADDRESS]  Adverse Event Severity  ................................ ................................ ....................  58 
[IP_ADDRESS]  Adverse Event  Causality  ................................ ................................ ..................  59 
[IP_ADDRESS]  Study Drug Action Taken  ................................ ................................ ................  59 
[IP_ADDRESS]  Adverse Event Outcome  ................................ ................................ ..................  59 
[IP_ADDRESS] Treatment Given ................................ ................................ ...............................  60 
13.1.2  Serious Adverse Events  ................................ ................................ ..........................  60 
[IP_ADDRESS] Definition of a Serious Adverse Event ................................ .............................  60 
[IP_ADDRESS]  Reporting and Documentation of Serious Adverse Events  ..............................  61 
[IP_ADDRESS]  Expedited Reporting and Investigator Safety Letters  ................................ ...... [ADDRESS_307616] Retention  ................................ ................................ ................................ .... 63 
13.2.8  Study Termination  ................................ ................................ ................................ .. 63 
13.2.9  End of Study  ................................ ................................ ................................ ...........  63 
13.3  Data Qual ity Assurance  ................................ ................................ ................................ .. 64 
13.4  Monitoring  ................................ ................................ ................................ ......................  64 
13.5  Electronic Data Capture  ................................ ................................ ................................ . 64 
13.6  Confidentiality and Disclosure  ................................ ................................ .......................  65 

Protocol VX20 -445-111, Version  3.0 Page 21 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  13.7  Publications and Clinical Study Report  ................................ ................................ ..........  65 
13.7.2  Clinical Study Report  ................................ ................................ .............................  66 
14 References  ................................ ................................ ................................ .............................  67 
APPENDIX A  Eligible MF CFTR Mutations  ................................ ................................ ....... 69 
APPENDIX B  Eligible ELX/TEZ/IVA -Responsive CFTR Mutations  ................................  [ADDRESS_307617] of Tables  
Table  2-1 Parts  A and B Doses  ................................ ................................ ...............................  6 
Table  3-1 Study VX20 -445-111, Part A Screening Period  ................................ .....................  8 
Table  3-2 Study VX20 -445-111, Part A Treatment Period and Safety Follow -up Visit  ........  9 
Table  3-3 Study VX20 -445-111, Part B Screening Period  ................................ ...................  11 
Table  3-4 Study VX20 -445-111, Part B Treatment Period and Safety Follow -up Visit  ...... 12 
Table  9-1 Parts  A and B Doses  ................................ ................................ .............................  32 
Table  9-2 Prohibited Medications  ................................ ................................ .........................  37 
Table  10-1 Study Drug: Dosing Form/Route/Strength  ................................ ...........................  [ADDRESS_307618] With an AE in the Study if the AE 
Incidence ( ) is 5% and 10%  ................................ ................................ ................  [ADDRESS_307619]  
IND Investigational New Drug (application) (US)  
IRB institutional review board  

Protocol VX20 -445-111, Version  3.0 Page 24 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  Abbreviation  Definition  
  
IV intravenous  
IVA ivacaftor  
IWRS  interactive web response system  
LCI lung clearance index  
LCI 2 5 number of lung turnovers required to reduce the end tidal inert gas concentration to 
1/40th of its starting value  
LUM  lumacaftor  
max maximum value  
MBW  Multiple -breath washout  
MF minimal function  
min minimum value  
MMRM  mixed -effects model for repeated  measures  
N total sample size  
P probability  
PC publication committee  
PD Pharmacodynamic(s)  
PEs physical examinations  
PEx pulmonary exacerbations  
P-gp P-glycoprotein  
PIs principal investigators  
PK Pharmacokinetic(s)  
PR PR interval, segment  
q12h  every 12 hours  
qAM  once every morning  
qd once daily  
qPM  once every evening  
QRS  the portion of an ECG comprising the Q, R, and S waves, together representing 
ventricular depolarization  
QT QT interval  
QTcF  QT interval corrected by [CONTACT_252860]’s formula  
RR interval from the onset of 1 QRS complex to the next; use R -R if using with 
“intervals”, i.e., “R -R interval”  
SAE  serious adverse event  
SAP statistical analysis plan  
SC steering committee  
SD standard deviation  
SI SI units (International System of Units)  
S[LOCATION_003]Rs  suspected, unexpected, serious adverse reaction  
SwCl  sweat chloride  
TC triple combination  
TE Treatment -emergent  

Protocol VX20 -445-111, Version  3.[ADDRESS_307620]  upper limit of normal  
US [LOCATION_002]  
[LOCATION_003]  [LOCATION_002] of America  
 
Protocol VX20 -445-111, Version  3.0 Page 26 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  5 INTRODUCTION  
5.1 Background  
Cystic fibrosis (CF) is an autosomal recessive genetic disease with serious morbidities and 
frequent premature mortality. CF affects more than 70,000  individuals worldwide1 
(approximately 31,000 in the US2 and 48,000  in the EU3). 
CF is caused by [CONTACT_155412]/or function of the CFTR protein due to mutations in the 
CFTR  gene.[ADDRESS_307621] common disease -causing mutation is F508del : approximately 84.7% of people with CF 
in the US and 81.1% in Europe have at least one F508del  allele.2, [ADDRESS_307622] a cure. CFTR modulators (i.e., correctors and potentiators) represent 
a major advancement in the treatment of CF because they are systemic therapi[INVESTIGATOR_252852].6, 7 The clinical testing and regulatory approval of CFTR modulators in certain 
countries for the treatment of people with CF caused by [CONTACT_252861]. These treatment regimens 
include ivacaftor (IVA) monotherapy (Kalydeco™), lumacaftor (LUM)/IVA dual combination 
therapy (Orkambi™), tezacaftor (TEZ)/IVA d ual combination therapy (Symdeko™, Symkevi™) 
and elexacaftor (ELX)/TEZ/IVA triple combination (TC) therapy.  
The ELX/TEZ/IVA regimen is the first medicine to demonstrate clinical benefit in patients with 
a single F508del allele, regardless of the mutation o f the second allele. A pi[INVESTIGATOR_9205]  3 
program in CF subjects 12  years of age or older demonstrated that ELX/TEZ/IVA provides 
substantial improvements in lung function, CFTR function, and nutritional status, and was 
generally safe and well tolerated with a  low rate of treatment discontinuation.  
5.2 Study Rationale  
Given the progressive nature of CF, there is a strong rationale for preventing disease progression 
by [CONTACT_252862]. Vertex evaluated ELX/TEZ/IVA TC therapy in Phase  3 studies 
in adult and adolescent CF subjects with 1 or 2 copi[INVESTIGATOR_1093] F508del  mutation, namely those 
with F/MF and F/F genotypes. Given the clinical benefit seen in a Phase 3 study of adults with 
CF with ELX/TEZ/IVA, the present study is designed to obtain pharmacokin etic (PK), safety, 
tolerability, and pharmacodynamic (PD) information to expand the evaluation of ELX/TEZ/IVA 
in the pediatric population 2  through  5 years of age (inclusive)  with F/MF or F/F genotypes 
(Part  A) or  who have at least 1 F508del  mutation in th e CFTR  gene or an ELX/TEZ/IVA -
responsive CFTR mutation  (Part B) . 
Protocol VX20 -445-111, Version  3.0 Page 27 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  6 STUDY OBJECTIVES  
6.1 Primary Objectives  
Part A  
• To evaluate the PK of ELX, TEZ, and IVA when dosed in TC  
• To evaluate the safety and tolerability of ELX/TEZ/IVA  
Part B  
To evaluate the safety and tolerability of ELX/TEZ/IVA  
6.2 Secondary Objectives  
Part A  
None  
Part B  
• To evaluate the PK of ELX, TEZ, and IVA  
• To evaluate the PD of ELX/TEZ/IVA  
• To evaluate the efficacy of ELX/TEZ/IVA  
7 STUDY ENDPOINTS  
7.1 Primary Endpoints  
Part A  
• PK parameters of ELX, TEZ, IVA, a nd relevant metabolites  
• Safety and tolerability assessments as determined by [CONTACT_20721] (AEs), clinical 
laboratory values, standard 12 -lead electrocardiograms (ECGs), vital signs, and pulse 
oximetry  
Part B  
Safety and tolerability assessments as determi ned by [CONTACT_2695], clinical laboratory values, standard 
12-lead ECGs, vital signs, and pulse oximetry  
7.2 Secondary Endpoints  
Part A  
None  
Part B  
• PK parameters of ELX, TEZ, IVA, and relevant metabolites  
• Absolute change in sweat chloride (SwCl) from baseline through Week 24  
• Absolute change in lung clearance index (LCI) 2.5 from baseline through Week  24 
Protocol VX20 -445-111, Version  3.0 Page 28 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  8 STUDY POPULATION  
Eligibility will be reviewed and documented by [CONTACT_155415]’s team before subjects are enrolled.  
Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be eligi ble. 
8.[ADDRESS_307623]’s legally appointed and authorized representative will sign and date an informed 
consent form (ICF).  
2. Subjects (males and females), 2  through 5  years of age, inclusive, on the date of informed 
consent (and assent, as applicab le). 
3. In Part  A, subjects must weigh ≥[ADDRESS_307624] weigh ≥10  kg at 
the Screening Visit.  
4. Confirmed diagnosis of CF as determined by [CONTACT_093].  
5. In Part A, subjects who  are homozygous for F508del (F/F genotype) or heterozygous for 
F508del  and an MF mutation that is not responsive to IVA and TEZ/IVA (F/MF genotypes; 
Appendix  A). In Part B,  subjects who have at least 1 F508del  mutation in the  CFTR  gene or 
an ELX/TEZ/IVA -responsive CFTR  mutation  (Appendix B ).  
• Genotype should be confirmed at the Screening Visit. This assessment does not need to 
be repeated for confirmed subjects in Part A who wish to participate in Part  B. 
• If the screening CFTR  genotype result is not received before the first dose of study drug, 
a previous CFTR  genotype laboratory report may be used to establish eligibility.  

Protocol VX20 -445-111, Version  3.0 Page 29 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  • Subjects who have been enrolled and whose screening genotype does not confirm study 
eligibility must be discontinued from the study (Section  9.9). 
6. Subjects with stable CF disease at the start of the Treatment Period as deemed by [CONTACT_1275].  
7. Subjec ts who are w illing to remain on a stable CF medication regimen (other than CFTR 
modulators) through Day  15 (Part  A) or through Week  24 (Part B) or, if applicable, through 
the Safety Follow -up Visit.  
8. As judged by [CONTACT_093], the parent or legal guardi an must be able to understand 
protocol requirements, restrictions, and instructions and the parent or legal guardian should 
be able to ensure that the subject will comply with and is likely to complete the study as 
planned.  
8.2 Exclusion Criteria  
1. History  of an y illness or any clinical condition that, in the opi[INVESTIGATOR_871], might 
confound the results of the study or pose an additional risk in administering study drug(s) to 
the subject. This includes, but is not limited to, the following:  
• Clinically significant cirrhosis with or without portal hypertension  
• Solid organ or hematological transplantation  
• Cancer  
2. Any clinically significant laboratory abnormalities at the Screening Visit that would interfere 
with the study assessments or pose an undue risk f or the subject (as deemed by [CONTACT_1275]).  
3. Any of the following abnormal laboratory values at screening:  
• Hemoglobin <10  g/dL  
• Total bilirubin, a spartate transaminase (AST), or alanine transaminase (ALT) ≥2  × upper 
limit of normal (ULN)  
• Alkaline phospha tase (ALP) or gamma -glutamyl transferase (GGT) ≥3  × ULN  
• Abnormal renal function defined as glomerular filtration rate ≤45  mL/min/1.73  m2 
(calculated by [CONTACT_14469] -Barratt equation)8 
4. An acute upper or lower respi[INVESTIGATOR_4416], PEx, or changes in therapy (including 
antibiotics) for pulmonary disease within 28  days before Day  1 (first dose of study drug).  
5. Lung infection with organisms associated with a more ra pid decline in pulmonary status 
(including, but not limited to, Burkholderia cenocepacia , Burkholderia dolosa , and 
Mycobacterium abscessus ). For subjects who have had a history of a positive culture, the 
investigator will apply the following criteria to es tablish whether the subject is free of 
infection with such organisms:  
• The subject has not had a respi[INVESTIGATOR_155390] 
12 months before the date of informed consent.  
Protocol VX20 -445-111, Version  3.0 Page 30 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  • The subject has had at least [ADDRESS_307625] recent one within the 6  months before the 
date of informed consent.  
6. An acute illness not related to CF (e.g., gastroenteritis) within [ADDRESS_307626] dose of 
study drug (Day  1). 
7. Ongoing or prior participation in an investigational drug study (including studies 
investigating ELX with or without coadministration with other s tudy drugs) within 28  days 
of the Screening Visit.  
• A washout period of [ADDRESS_307627] elapse before the Screening Visit.  
• The duration of the elapsed time may be longer  if required by [CONTACT_427].  
Note: Ongoing participation in a noninterventional study (including observational 
studies) is permitted.  
8. Use of restricted medication within specified duration before the first dose of study drug as 
defined in Table  9-2. 
9. The subject or a close relative of the subject is the investigator or a subinvestigator, research 
assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of 
the study.  
10. Part B only : Elevated serum ALT or AST ≥3  × ULN or total bilirubin ≥2  × ULN in the 
previous year.  
9 STUDY IMPLEMENTATION  
9.1 Study Design  
This is a Phase  3, 2-part (Parts  A and  B), multicenter study evaluati ng the safety, tolerability, 
PK, PD, and efficacy of ELX/TEZ/IVA in CF subjects 2  through 5  years of age (inclusive).  
Part  A 
A schematic of the study design for Part  A is provided in Figure  9-1. Approximately 14  subjects 
(F/F or F/MF genotypes) will be enrolled. During the Treatment Period, subjects will be 
administered ELX/TEZ/IVA for approximately 15  days ( Table  9-1). Safety, tolerability, and 
available PK data from Part  A will be reviewed by [CONTACT_252863](s) 
chosen for Part  B. Additional subjects may be enrolled as needed in Part  A, based on emerging 
PK data, in order to provide sufficient information to select the dose(s) for Part  B. Subjects who 
participate in Part  A may participate in Part  B. 
Protocol VX20 -445-111, Version  3.[ADDRESS_307628] Weight at Day  1 ELX Dose  TEZ Dose  IVA Dose  
Part  A    
≥14 kg only  100 mg qd  50 mg qd  75 mg q12h  
Part  B    
≥14 kg 100 mg qd  50 mg qd  75 mg q12h  
≥10 kg to <14  kg 80 mg qd  40 mg qd  60 mg qAM  
59.5 mg qPM  
ELX: elexacaftor; IVA: ivacaftor; qAM: once every morning; qd: once daily; qPM: once every evening; 
q12h:  every 12  hours; TEZ: tezacaftor  
9.1.1  Screening  
Screening Visit assessments are listed in Table  3-1 (Part  A) and Table  3-3 (Part  B). 
Screening will occur within 28  days before administration of study drug. The investigator (or an 
appropriate authorized designee at the study site) will obtain informed consent and assent for 
each subject before any st udy procedure takes place.  
Subjects who participate in Part  A may participate in Part  B. Subjects from Part  A will be 
screened for Part  B and must be deemed eligible before enrolling in Part  B. 
To prepare for study participation, subjects will be instructe d on the study restrictions 
(Section  9.4) and concomitant medications (Section  9.5). 
[IP_ADDRESS]  Repetition of Screening Assessments  
Part A  
Screening assessments may be repeated once to establish study eligibility. If repeat values of the 
individual assessment(s) are within the eligibility criteria and comp leted within the screening 
window, then the subject may qualify for the study.  
Part B  
Screening assessments may be repeated once to establish study eligibility, except for LFT 
assessment(s) if LFT values at the original Screening Visit were elevated (total  bilirubin, AST, or 
ALT ≥2  × ULN).  If repeat values of the individual assessment(s) are within the eligibility criteria 
and completed within the screening window, then the subject may qualify for the study.  
Repetition of  LFT screening assessment(s) that do  not meet eligibility criteria is not permitted, 
with the following exceptions:   
• If there is clear evidence of a laboratory error or equipment malfunction, then collection of a 
repeat sample for the appropriate laboratory test may be permitted after discus sion with the 
Vertex medical monitor or authorized designee.  
• If an acute non -CF etiology is identified for elevated transaminases, exclusionary LFT levels 
may be retested within [ADDRESS_307629] been completed within the screening 
window or extended screening window (Section  [IP_ADDRESS] ), then the results can be cons idered 
qualifying for the study.  
Protocol VX20 -445-111, Version  3.0 Page 33 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  [IP_ADDRESS]  Rescreening  
Subjects may be rescreened once. If a subject is rescreened, the subject will provide informed 
consent and assent (as applicable), and all screening assessments will be repeated, except for:  
• CFTR  genotypi[INVESTIGATOR_007]  
• Opht halmologic examination (if performed within 3  months before the date of informed 
consent)  
If a subject is rescreened, a new screening window will begin when the first rescreening 
assessment has been initiated.  
In Part B, rescreening is not allowed if the L FT values obtained at the original Screening Visit 
and retesting (if applicable) were exclusionary (i.e., total bilirubin, AST, or ALT ≥2 × ULN).  
[IP_ADDRESS]  Extension of Screening Period Window  
A subject may have the Screening Period window extended by 2  weeks for th e following 
reasons:  
• Repetition of the Screening Period assessments (Section  [IP_ADDRESS] ) 
• Unexpected operational or logistic delays, or to meet the eligibility criteria  
• Scheduling of ophthalmologic examination (Section  11.5.5 ) 
9.1.2  Treatment Period  
Treatment Period assessments are listed in Table  3-2 (Part  A) and Table  3-4 (Part  B). 
The Treatment P eriod will last approximately [ADDRESS_307630] scheduled study visit and 
complete assessments for all study visits, as described in Section  9.1.4 . 
9.1.3  Follow -up 
The Safety Follow -up Visit is scheduled to occur 28 (±  7) days after the last dose of study drug. 
The Safety Follow -up Visit is not required for Part  B subjects who complete the Week  [ADDRESS_307631] prematurely discontinues study drug treatment, an Early Termination of Treatment 
(ETT)  Visit should be scheduled as soon as possible after the decision to discontinue treatment. 
Subjects who prematurely discontinue treatment will also be required to complete the Safety 
Follow -up Visit ( Table  3-2 for Part  A and Table  3-4 for Part  B), if applicable (Section  9.1.3 ). 
If the ETT Visit occurs [ADDRESS_307632] withdraws from the study and also withdraws consent or assent, no further 
assessments will be performed. Vertex may retain and continue to use any data and samples 
collected before such withdrawal of consent or assent (Section  9.9). 
9.1.[ADDRESS_307633] to follow -up if both of the following occur:  
• The subject misses 2  consecutive study visits (telephone contact [INVESTIGATOR_1238]/or clinic visit) and is 
subsequently unable to be contact[CONTACT_5143] (3  documented attempts by [CONTACT_155417] 2  weeks following the second missed visit)  
• The subject does not respond within [ADDRESS_307634] is defined as 1 of the following:  
Part  A 
• For subjects who complete the Treatment Period: the Safety Follow -up Visit  
• For subjects who prematurely discontinue study drug treatment but do not withdraw consent 
(and assent, as applicable): the latest of the Day  15 Visit, ETT Visit, or Safety Follow -up 
Visit  
• For subjects who withdraw consent or assent: date of withdrawal of conse nt or assent, 
whichever is earlier (Section  9.9) 
Part  B 
• For subjects who complete the Treatment Period and enter an OLE safety study within 
28 days of  the Week  24 Visit: the Week  24 Visit  
• For subjects who complete the Treatment Period and do not enter an OLE safety study within 
28 days of the Week  24 Visit: the Safety Follow -up Visit  
• For subjects who prematurely discontinue study drug treatment but do not withdraw consent 
(and assent, as applicable): the latest of the Week  24 Visit, ETT Visit, or Safety Follow -up 
Visit (if required)  
• For subjects who withdraw consent or assent: date of withdrawal of consent or assent, 
whichever is earlier (Section  9.9) 
If subjects are lost to follow -up (Section  9.1.5 ), the date of completion of study participation  will 
be defined as the date of the last contact.  
The end of study is defined in Section  13.2.9 . 
9.1.7  Data Monitoring Committee  
Safety and tolerability data will be reviewed by a data monitoring committee (DMC) to ensure 
the safety of the subjects (Section  12.5). Procedural details of the DMC’s structure and function, 
frequency of meetings, and data planned for review will be in the DMC charter. The DMC 
charter will be finalized before the first subject is screened.  
Protocol VX20 -445-111, Version  3.0 Page 35 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  9.1.8  Use of Remote Measures  in Extenuating Circumstances  
Study visits should be performed in the clinic as specified in Table  3-2 and Table  3-4, if at all 
possible . However, under extenuating circumstances, remote measures may be implemented 
(e.g., if a subject is unable to travel to the study site due to safety concerns and/or l ocal 
restrictions related to COVID -19 or other emerging events). The decision whether to conduct a 
study visit remotely or in clinic will be at the discretion of the investigator; if the investigator 
determines that study visits will be conducted remotely,  the medical monitor should be notified. 
The Screening visits (including initial consent) and Day [ADDRESS_307635] be performed in the clinic.  
Whenever local regulations or site practice do not allow remote measures, visits will be 
conducted at the site.  
The following remote measures may be implemented. Additional details can be found in the 
Study Reference Manual.  
• Reconsent may be obtained remotely in writing (or verbally, with follow -up written 
confirmation), as allowed by [CONTACT_427].  
• Study drug may be shipped directly from the site to the subject, as applicable and as allowed 
by [CONTACT_427].  
• Study visits (except at Screening and Day 1) may be conducted as in -home visits by [CONTACT_134323].  
• Study assessments may be performed or overseen by q ualified personnel conducting the 
in-home visits, except for MBW assessments.  
• Remote monitoring visits may be implemented as applicable (including remote source data 
verification) and as allowed per local regulations.   
9.2 Method of Assigning Subjects to Treatment Groups  
This is an open -label study.  
9.3 Rationale for Study Elements  
9.3.1  Study Design  
This open -label study is designed to evaluate the PK and safety of ELX/TEZ/IVA in this 
pediatric CF population and confirm the doses and appropriate weight cut -off. The  design is 
consistent with ICH guidelines for the study of human subjects, especially children, and balances 
safety concerns with potential benefits for the individual.  
9.3.2  Study Population  
This study will enroll CF subjects 2 through 5 years of age (inclusive ). Part A will enroll CF 
subjects  with F/MF or F/F genotypes . Part B will enroll CF subjects who have at least 1  F508del  
mutation in the  CFTR  gene or an  ELX/TEZ/ IVA-responsive CFTR  mutation  as listed in  
Appendix B . ELX/TEZ/IVA is expected to provide clinical benefit to these patients based on the 
results of Phase  3 studies (Studies VX17 -445-102 and VX17 -445-103), which demonstrated the 
efficacy and safety of ELX/TEZ/IVA in CF subjects ≥[ADDRESS_307636] F/MF and F/F 
genot ypes. A pi[INVESTIGATOR_252853]/TEZ/IVA in CF subjects 6 through 11  years of age 
(inclusive; VX18 -445-106) demonstrated efficacy and safety similar to results seen in CF 
subjects ≥12  years of age.  
Protocol VX20 -445-111, Version  3.0 Page 36 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  Given the progressive nature of CF, there is a strong rational e for treating patients earlier in life. 
Experience with other CFTR modulators in pediatric subjects 2 through 5  years of age, including 
LUM/IVA and IVA, suggests that the safety profile of ELX/TEZ/IVA will be similar in children 
and adults, which supports  evaluation of ELX/TEZ/IVA in pediatric subjects in the present 
study.  
9.3.3  Study Drug Dose and Duration  
An ELX dose of 200  mg once daily (qd) in TC with TEZ 100  mg qd/IVA 150  mg every 12 hours 
(q12h) was evaluated in pi[INVESTIGATOR_9205]  3 studies of adult and adoles cent (≥12  years of age) CF 
subjects with F/MF and F/F genotypes. These studies demonstrated that treatment with this 
ELX/TEZ/IVA regimen resulted in rapid, robust, clinically meaningful, and statistically 
significant improvements in all primary and key sec ondary efficacy and PD endpoints . 
TC regimens of ELX 200  mg qd/TEZ 100  mg qd/IVA 150  mg q12h and ELX 100  mg qd/TEZ 
50 mg qd/IVA 75  mg q12h were  evaluat ed in a Phase  3 study of pediatric ( 6 to <12  years of age) 
CF subjects with F/MF and F/F genotypes.  This study demonstrated safety  and efficacy  similar 
to results seen in CF subjects ≥12 years of age.  
Part  A 
The TC regimen of ELX 100  mg qd/TEZ 50  mg qd/IVA 75  mg q12h selected for evaluation in 
Part A is the same dose studied in lower weight 6 to <12  year old subjects, and was based on 
population PK modeling. This modeling used TC data from CF subjects >6 years of age and 
simulated exposures for body weights typi[INVESTIGATOR_252854] 2 - to <6 -year-old population. The 
simulations indicated that the proposed dosing re gimen for Part A is predicted to provide ELX, 
TEZ, and IVA exposures similar to those shown to be safe and efficacious in adults from Phase  3 
studies.  
Part  B 
For Part  B, subjects will be administered either ELX 100  mg qd/TEZ 50  mg qd/IVA 75  mg q12h 
or ELX 80 mg qd/TEZ 40  mg qd/IVA 60  mg once every morning (qAM) and 59.5  mg once 
every evening (qPM). The appropriate weight cut -off for the switch between these regimens was 
determined based on population PK modeling that included PK data from Part  A and additio nal 
PK data from TC studies conducted in CF subjects >6 years of age.  
Duration of Dosing  
The 15 -day duration of dosing in Part  A provides an adequate assessment PK, safety, and 
tolerability of ELX/TEZ/IVA before exposing subjects to a longer treatment dura tion of 
[ADDRESS_307637] safety assessments.  
Protocol VX20 -445-111, Version  3.0 Page 37 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  LCI is a measure of ventilation inhomogenei ty assessed by [CONTACT_27873] -breath washout (MBW) that 
is based on tidal breathing techniques that have been evaluated in patients as young as infants.9, [ADDRESS_307638] shown that LCI correlates with forced expi[INVESTIGATOR_3741] 1  second (FEV 1) in its 
ability to measure airway di sease and can detect lung disease at an earlier stage than 
spi[INVESTIGATOR_038].11, 12 Furthermore, data from Study  VX10 -770-106 in CF patients with an FEV 1 
>90% showed LCI to be a more sensitive outcome measure than FEV 1. As with spi[INVESTIGATOR_252855], performing MBW assessments in young children ca n be difficult.13 Therefore, only 
subjects who are ≥[ADDRESS_307639] the potential to alter the 
exposure of ELX, TEZ, or IVA, are prohibited.  Moderate and strong 
CYP3A inhibitors 
(except 
ciprofloxacin)a None allowed 
within [ADDRESS_307640] 
dose of the study 
drug on Day  1 None allowed 
through 
completion of 
study 
participation  
CFTR modulators 
(investigational or 
approved), except for 
study drugs  None allowed 
within [ADDRESS_307641] dose of 
study drug  These agents may confound the results of this 
study.  
CYP:  cytochrome P450; ELX: elexacaftor; IVA:  ivacaftor; TEZ:  tezacaftor  
a Ciprofloxacin is not a moderate CYP3A inhibitor on the basis of results of a drug -drug interaction study 
conducted with IVA, a sensitive CYP3A substrate (Kalydeco [ivacaftor] US Package Insert).  
9.[ADDRESS_307642]’s source 
documentation for medications taken within [ADDRESS_307643]’s source documents.  
• Subjects should remain on a stable treatment regimen for their CF from [ADDRESS_307644] 28  days 
before the Day  1 Visit. Subjects should not initiate long -term treatment with new medication 
from 28  days before the Day  1 Visit through completion of study par ticipation . Guidelines 
for stable treatment regimens for CF are as follows:  
o Subjects who are taking inhaled tobramycin or other chronically inhaled antibiotics 
should remain on that regimen throughout the study.  
o Subjects who cycle onto and off of an inhale d antibiotic should continue on their prior 
schedule. The timing of the first dose of study drug on the Day  1 Visit should be 
synchronized as closely as possible (e.g., not more than ±  3 days) to the first day in 
the cycle onto the inhaled antibiotic.  
o Subjects who alternate between [ADDRESS_307645] dose of study drug on 
the Day  1 Visit should be synchronized as closely as possible (e.g., not more than 
± 3 days) to the first day in the cycle onto 1 of the inhaled antibiotics.  
• Subjects may receive doses of prednisone or prednisolone of up to 10  mg/day chronically, or 
up to 60  mg daily for up to 5  days.  
• ELX may inhibit OATP1B1 and OATP1B3, which may increase the exposure of medicinal 
products that are substrates for these transporters. Substrates such as statins, glyburide, 
nateglinide, and repaglinide should be used with caution.  
• IVA is a weak inhibitor of P -glycoprotein (P -gp). Administration of IVA may increas e 
systemic exposure of medicinal products that are sensitive substrates of P -gp, which may 
increase or prolong their therapeutic effect and adverse reactions. Digoxin or other substrates 
of P-gp with a narrow therapeutic index, such as cyclosporine, everol imus, sirolimus, and 
tacrolimus, should be used with caution and appropriate monitoring.  
• IVA may inhibit CYP2C9; therefore, during coadministration with warfarin, additional 
monitoring of the international normalized ratio is recommended. Other medicinal products 
that are CYP2C9 substrates for which exposure may be increased include glimepi[INVESTIGATOR_168781]; these should be used with caution.  
• Information about bronchodilator use during the study will be collected and documented. 
Subjects who are using a b ronchodilator should have their MBW assessments performed 
according to the guidelines provided in Section  11.4.2 . 
9.6 Administration  
9.6.1  Dosing  
Study drug will be orally administered with the approved foods and liquids listed in the Study 
Manual (e.g., apple sauce). The d oses to be administered are shown in Table  9-1. 
Protocol VX20 -445-111, Version  3.[ADDRESS_307646] “CF” meal or  snack or a standard meal  
according to the following guidelines:  
1. On days of scheduled visits, the morning dose of study drug will be administered at the site 
after predose assessments have been completed.  
2. All doses of study drug (morning and evening, as ap plicable) should be administered at 
approximately every 12  hours (±  1 hour for Part  A and ±  2 hours for Part  B) on each dosing 
occasion. For example, if the morning doses of study drug are administered at 08:00  hour on 
Day 1, all subsequent morning doses s hould be administered between 07:00  hour and 
09:00  hour for Part  A, and between 06:00  hour and 10:00  hour for Part  B. 
3. At the Day  1 Visit, all subjects will be observed for 4  hours after the morning dose of the 
study drug.  
4. The date, amount taken, and time o f study drug administration including whether food was 
taken with each dose, will be recorded for 2  days before PK sample collection and on the 
days of PK sample collection.  
5. For visits after the Day  1 Visit, subjects will be instructed to bring all used an d unused study 
drug to the site; study drug will be dispensed at each visit, as appropriate.  
6. Part  A: At the Day  15 Visit, only the morning dose of study drug will be administered.  
Part  B: At the Week  [ADDRESS_307647] should take 
the missed dose as soon as p ossible and continue on the original schedule.  
Morning dose: If more than [ADDRESS_307648] 
should take the missed dose as soon as possible and should not take the evening dose.  
Evening dose:  If more than [ADDRESS_307649] 
should not take the missed dose. The next scheduled morning dose should be taken at the usual 
time.  
Morning and evening doses should not be taken at the same time.  
9.7 Dose Modificati on for Toxicity  
No dose modifications for toxicity are allowed. If any unacceptable toxicity arises, individual 
subjects will discontinue dosing (Section  9.1.4). 
9.[ADDRESS_307650] interrupted study drug for >[ADDRESS_307651]’s clinical stability and should consider resumption of study 
drug only after the subject is clinically stable  and there is no comorbidity or condition that, in the 
opi[INVESTIGATOR_871], might confound the results of the stud y or pose an additional risk in 
administering study drug to the subject.  
Protocol VX20 -445-111, Version  3.0 Page 40 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  The medical monitor should be notified of an interruption of study drug that lasts >[ADDRESS_307652] >3  × ULN and total 
bilirubin >2  × ULN that are derived from centrally submitted samples.  
Subjects with new treatment -emergent ALT or AST elevations of >3  × ULN, with or without 
total bilirubin >2  × ULN, must be followed closely, including confi rmatory testing performed by 
[CONTACT_66768] [ADDRESS_307653] the tests repeated and sent to the central laboratory as soon as possible (ideally within 
48 to 72  hours).  
Study drug admi nistration must be interrupted  immediately (prior to confirmatory testing) if 
any of the following criteria are met:  
• ALT or AST >8  × ULN  
• ALT or AST >5  × ULN for more than 2  weeks  
• ALT or AST >3  × ULN, in association with total bilirubin >2  × ULN and/or clin ical jaundice  
A thorough investigation of potential causes should be conducted, and the subject should be 
followed closely for clinical progression.  
Study drug administration must be discontinued  if the following criteria are met:  
• Subsequent ALT or AST val ues confirm the initial elevation that satisfied the interruption 
rule (above), and no convincing alternative etiology (e.g.,  acetaminophen use, viral hepatitis, 
alcohol ingestion) is identified, regardless of whether transaminase levels have improved  
All subjects in whom treatment is discontinued for elevated transaminases (and bilirubin, as 
applicable) should have these levels monitored closely until levels normalize or return to 
baseline.  
If an alternative, reversible cause of transaminase elevation with  or without increased bilirubin or 
clinical jaundice has been identified , study drug administration may be resumed once 
transaminases return to baseline or are ≤2  × ULN, whichever is higher. Regardless of the 
duration of interruption, the medical monitor s hould be notified prior to resumption of study 
drug. Upon resumption of study drug, transaminases and bilirubin should be assessed weekly for 
4 weeks. If a protocol -defined transaminase elevation interruption threshold recurs within 
4 weeks of rechallenge with the study drug (with confirmation of the initial elevation by [CONTACT_155421] 48  to 72  hours), then the study drug must be permanently discontinued, regardless 
of the presumed etiology.  
Protocol VX20 -445-111, Version  3.[ADDRESS_307654] develops a generalized rash of Grade 3 or higher (Section  [IP_ADDRESS] ), or 
a rash that is considered a serious adverse event (SAE).  The investigator will notify the medical 
monitor of any rash that results in interruption of study drug, is Grade  3 or higher 
(Section  [IP_ADDRESS] ), or is an SAE.  Investigators should consider additional evaluation including 
laboratory testing (e.g., complete blood count with dif ferential, liver function tests), photographs 
of the rash, and dermatology consultation. The investigator may consider resumption of study 
drug if considered clinically appropriate.  
9.9 Removal of Subjects  
Subjects (or subjects' parent/legal guardian) may with draw from the study at any time at their 
own request. Subjects may be withdrawn at any time at the discretion of the investigator or 
Vertex for safety, behavior, noncompliance (study drug dosing or study procedures), or 
administrative reasons. A subject wh o withdraws (or is withdrawn by [CONTACT_7078]/legal guardian) 
from study drug treatment will continue to be followed unless the subject (or parent/legal 
guardian) withdraws consent.  
In addition, a subject must be discontinued from study drug treatment if the subj ect meets any of 
the following criteria:  
• Has a screening CFTR  genotype that does not confirm study eligibility if a previous CFTR  
genotype laboratory report was used to establish eligibility. These subjects must be 
discontinued from the study (Section  8.1) 
• Meets any of the stoppi[INVESTIGATOR_007] (discontinuation) criteria (Section  9.8) 
Subjects who discontinue study treatment early should continue to return for study assessments, 
as noted in Section 9.1.[ADDRESS_307655](s), request that the subject return for a Safety Follow -up Visit, if 
applicable (see Section  9.1.4 ), and follow  up with the subject regarding any unresolved AEs.  
If a subject withdraws consent for the study, no further assessments will be performed. Vertex 
may retain and continue using the study data and samples after the study ends, and  may use the 
samples and information in the development of the study compound, for other drugs and 
diagnostics, in publications and presentations, and for education purposes. If a subject withdraws 
from the study, the study data and samples collected will remain part of the study. A subject will 
not be able to request the withdrawal of his/her information from the study data. A subject may 
request destruction of the samples collected from him/her during the study as long as those 
samples can be identified a s his/her samples.  
Protocol VX20 -445-111, Version  3.0 Page 42 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  9.10 Replacement of Subjects  
Part  A 
Subjects who withdraw or are withdrawn for nonsafety reasons during the study drug Treatment 
Period may be replaced as needed in Part  A, based on emerging PK data, to confirm the dose(s) 
for Part B.  
Part B  
Subjects who withdraw or are withdrawn for nonsafety reasons during the study drug Treatment 
Period may be replaced at Vertex's discretion.  
10 STUDY DRUG INFORMATI ON AND MANAGEMENT  
10.1 Preparation and Dispensing  
Study drug may be dispensed only under the supervis ion of the investigator or an authorized 
designee and only for administration to the study subjects. An interactive web response system 
(IWRS) will be used to dispense dosage based on subject weight.  
10.[ADDRESS_307656] ied in capsules in bottles in Part A and in sachets in Part B by 
[CONTACT_139383]. Study drug labeling will be in compliance with applicable local and national regulations. 
Additional details regarding packaging, labeling, and dispensing for study drug will be in th e 
Pharmacy Manual.  
10.3 Study Drug Supply, Storage, and Handling  
Table  10-1 provides the study drug information. The investigator, or an authorized designe e 
(e.g., a licensed pharmacist), will ensure that all investigational product is stored in a secured 
area, under recommended storage conditions, and in accordance with applicable regulatory 
requirements. To ensure adequate records, all study drugs will be accounted for as described in 
Section  10.4 or via the drug accountability forms as instructed by [CONTACT_139383].  
Detailed instructions regarding the storage , handling, and dispensation of the study drug will be 
provided in the Pharmacy Manual.  
Table  10-1 Study Drug: Dosing Form/Route/Strength  
Drug Name, Dosing Form, Route  Study Drug Strength  
Part  A: 
All Subjects  Part  B: 
Subjects ≥10 kg to 
<14 kg at Day  1 Part  B: 
Subjects ≥14  kg at 
Day 1 
ELX/TEZ/IVA, FDC granules, oral     
ELX  100 mg 80 mg 100 mg 
TEZ 50 mg 40 mg 50 mg 
IVA 75 mg 60 mg 75 mg 
IVA, granules, oral  75 mg 59.5 mg  75 mg 
ELX: elexacaftor; FDC:  fixed -dose combination; IVA: ivacaftor; TEZ: tezacaftor  
Protocol VX20 -445-111, Version  3.[ADDRESS_307657] or designated study site staff will maintain information about the dates and 
amounts of (1) study drug received; (2) study drug dispensed to the subjects; and (3) study drug 
returned by [CONTACT_748]. Subjects will be instructed to return all  used and unused materials 
associated with the study drug to the site. These materials will be retained at the site according to 
instructions provided by [CONTACT_139411]. The study monitor will review study drug 
records and inventory throughout the study.  
If a site uses a site -specific drug accountability system and/or process, including processes 
associated with the destruction of returned materials, the process must be documented and 
approved by [CONTACT_139383]. The study monitor must review the drug accou ntability documentation on a 
regular basis. The study monitor will promptly communicate to Vertex any discrepancies he/she 
is unable to resolve with the site.  
10.[ADDRESS_307658] Vertex with 
any recall activities (as applicable) and place impacted investigational medic inal product (IMP) 
in quarantine when requested.  
10.[ADDRESS_307659] is compliant w ith 
study drug dosing and remind the subjects’ parents or legal guardians of study drug dosing 
requirements. Compliance will also be assessed by [CONTACT_252864].  
If a subject’s parent or legal guardian demonstrates continued noncompliance of study  drug 
dosing despi[INVESTIGATOR_693], the investigator should consider discontinuing the subject 
from the study.  
10.7 Blinding and Unblinding  
This will be an open -label study; however, subjects and their parent or legal guardian should not 
be informed of th eir study -related LCI, SwCl,  results during the 
Treatment Period (Part B only), regardless if the subject permanently discontinues treatment.  
[ADDRESS_307660] and disease characteristics include the following: demographics, medical history, height, 
and weight . 

Protocol VX20 -445-111, Version  3.[ADDRESS_307661] time of the sample collection will be noted.  
Table  11-1 Acceptable Pharmacokinetic Sampling Windows  
Sampling Time  Time From Scheduled Sampling Allowed  
Predose (before morning dose)  within 60  minutes before dosing  
>0.25 and ≤6  hours after morning dose   [ADDRESS_307662] operating procedures. A description of the assay and validation data will be 
provided in separate reports.  

Protocol VX20 -445-111, Version  3.0 Page 45 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  11.4 Efficacy and Pharmacodynamics (Part  B Only)  
11.4.[ADDRESS_307663] be conducted predose relative to the morning dose of 
study drug during the Treatment Period. At each time point, 2  samples will be collected, 
1 sample from each arm (left and right).  
11.4.2  Multiple -breath Washout  
The N 2-MBW testing will be performed in multiple replicates for subjects ≥[ADDRESS_307664]:  
• withheld their short -acting bronchodilators (e.g.,  albuterol) or anticholinergic 
(e.g.,  ipratropi[INVESTIGATOR_1893] [Atrovent®]) for more than [ADDRESS_307665];  
• withheld their long -acting bronchodilator (e.g.,  salmeterol) for more than [ADDRESS_307666]; and  
• withheld their once -daily, long -acting bronchodilator (e.g.,  tiotropi[INVESTIGATOR_1893] [Spi[INVESTIGATOR_35444]®]) 
for more than [ADDRESS_307667] be performed before study drug dosing  (Section  9.6.1 ) at 
approximately the same time at each visit. In the event that a subject forgets to withhold 
bronchodilator(s), MBW testing should b e performed according to the following:  
• If a subject’s Day  [ADDRESS_307668] will be obtained for 
that visit only, and the visit will not be rescheduled.  
• If, on Day  1, the subject forgets to withhold his/her dose of bronchodilator, the MBW test 
should be performed post -bronchodilator, and all subsequent MBW tests (according to the 
schedule of assessments) should be performed post -bronchodilator.  
• Each MBW test will be recorded in the source documents as pre - or post -bronchodilator.  
Subjects and parents/legal guardians should not be informed of study -related LCI results.  
Detailed MBW procedures will be supplied separately in a Study Ma nual.  

Protocol VX20 -445-111, Version  3.0 Page 47 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  

Protocol VX20 -445-111, Version  3.0 Page 48 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  11.5 Safety  
Safety evaluations will include reporting of AEs, clinical laboratory assessments, physical 
examinations (PEs) , clinical evaluation of vital signs, pulse oximetry, st andard [ADDRESS_307669] dose of study drug will be captured as an AE if those findings meet the 
definition of an AE. Demographic data collected at the Screening Visit will b e included in the 
study database.  
11.5.1  Adverse Events  
All AEs will be assessed, documented, and reported in accordance with current ICH  E6 GCP 
Guidelines. Section  13.1 outlines the definitions, collection periods, criteria, and procedures for 
documenting, grading, and reporting AEs. Electronic AE case report form (CRF) completion 
guidelines for investigators as well as training will be provided.  
11.5.2  Clinical L aboratory Assessments  
Blood and urine samples will be analyzed at a central laboratory. A local laboratory may be used 
for the Week  20 (Part  B) assessments if the subject cannot return to the site for a blood draw. All 
blood samples will be collected while  subjects are in a seated or supi[INVESTIGATOR_2547]. To minimize 
the total amount of blood taken  during screening and at Day [ADDRESS_307670] results that are abnormal and considered clinically significant will be 
reported as AEs (see Section  13.1). 
The safety laboratory test panels are shown in Table  11-2. 
Protocol VX20 -445-111, Version  3.[ADDRESS_307671] bilirubin  
Alkaline phosphatase  
Aspartate transaminase  
Alanine transaminase  
Amylase  
Lipase  
Gamma -glutamyl transferase   
Protein  
Albumin  
Creatine kinase  
Cholesterol  Hemoglobin  
Erythrocytes  
Mean corpuscular v olume  
Platelets  
Reticulocytes  
Leukocytes  
Differential (absolute and percent):  
Eosinophils  
Basophils  
Neutrophils  
Lymphocytes  
Monocytes  
Coagulation  
Activated partial thromboplastin time  
Prothrombin time  
Prothrombin time International 
Normalized Ratio  Leukocyte esterase  
Nitrite  
Urobilinogen  
Urine protein  
pH 
Urine blood  
Specific gravity  
Urine ketones  
Urine bilirubin  
Urine glucose  
a If urinalysis results are positive for leukocyte esterase, nitrite, protein, or blood, microscopic examination of 
urine will be done, and results will be provided for leukocytes, erythrocytes, crystals, bacteria, and casts.  
b If blood urea nitrogen cannot be collected, urea may be substituted.  
CF genotype (Screening Period only) : CF genotypi[INVESTIGATOR_252856] l subjects. If the 
CFTR  genotype result is not received before the first dose of study drug, a previous CFTR  
genotype laboratory report may be used to establish eligibility (Section  8.1). Subjects who have 
been enrolled and whose screening genotype does not confirm study eligibility must be 
discontinued from the study (Section  9.9). This assessment does not need to be repeated in the 
case of rescreening or for confirmed subjects in Part  A who wish to participate in Part  B. 
Additional Evaluations : Additional clinical lab oratory evaluations will be performed at other 
times if judged by [CONTACT_252865].  
For the purposes of study conduct and unless noted otherwise, only laboratory tests done in the 
central laboratory may be used. Local laborato ries may be used at the discretion of the local 
investigator for management of urgent medical issues. If a local laboratory test value is found to 
be abnormal and clinically significant, it will be verified by [CONTACT_252866]. If it is not possible to send a 
timely specimen to the central laboratory (e.g.,  the subject was hospi[INVESTIGATOR_94248]), the 
investigator may base the assessment of an AE on the local laboratory va lue. 
11.5.[ADDRESS_307672] 
study visits. At other visits, symptom -directed PEs and symptom -directed vital signs assessments 
can be performed at the discretion of the investigator or healthc are provider . 
Protocol VX20 -445-111, Version  3.0 Page 50 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  A PE includes a review of the following systems: head, neck, and thyroid; eyes, ears, nose, and 
throat (EENT); respi[INVESTIGATOR_696]; cardiovascular; lymph nodes; abdomen; skin; musculoskeletal; and 
neurological. Breast, anorectal, and genital examinat ions will be performed when medically 
indicated. After screening, any clinically significant abnormal findings in PEs will be reported as 
AEs.  
Height and weight will be measured with shoes off and before the dose of the study drug during 
the Treatment Peri od. 
Vital signs include blood pressure (systolic and diastolic), temperature, pulse rate, and 
respi[INVESTIGATOR_1487]. The subject will be instructed to rest for at least [ADDRESS_307673] 
12-lead ECGs will be performed at any other time if clinically indicated. The performance of all 
ECGs will adhere to the following guidelines:  
• The ECG will be done before any other procedures that may affect heart rat e, such as blood 
draws.  
• The subject will be instructed to rest for at least 5  minutes before having an ECG.  
• The test should be performed in the supi[INVESTIGATOR_2547].  
A printout of the ECG traces will be made for safety review by [CONTACT_168795]. Clinically significant ECG abnormalities occurring during the study 
through completion of study participation  will be recorded as AEs.  
To ensure safety of the subjects, a qualified individual at the study site will make compariso ns to 
baseline measurements. If the QTcF is increased by >60  msec from the baseline or an absolute 
QTcF value is ≥500  msec for any scheduled ECG, 2  additional ECGs will be performed 
approximately 2  to 4 minutes apart to confirm the original measurement. If  either of the QTcF 
values from these repeated ECGs remains above the threshold value (>60  msec from baseline or 
≥500  msec), a single ECG will be repeated at least hourly until QTcF values from [ADDRESS_307674] or optometris t and will 
include:  
• measurement of best -corrected distance visual acuity of each eye; and  
• pharmacologically dilated examination of the lens with a slit lamp.  
Protocol VX20 -445-111, Version  3.[ADDRESS_307675] prematurely discontinues study d rug, in which case this examination should occur by [CONTACT_252867] -up Visit (or ETT  Visit for subjects who do not complete a Safety Follow -up 
Visit), as described in  Table  3-4. 
11.5.6  Contraception and Pregnancy  
Not applicable.  
12 STATISTICAL ANALYSIS  
This section presents a summary of the principal features of the planned analyses. Statistical 
analysis details will be in th e statistical analysis plan (SAP), and clinical pharmacologic analysis 
details will be provided in the clinical pharmacology analysis plan (CPAP), both of which will be 
finalized before clinical database lock.  
12.[ADDRESS_307676] 
80% power to target a 95% CI within 60% and 140% of the geometric mean estimate of 
clearance for ELX and M23 -445. 
Part  B 
No formal power calculation is performed. The number of subjects in Part  B is deemed adequate 
to meet the primary safety  objective. The planned enrollment is approximately 70  subjects. 
Assuming a dropout rate of 10% or 20%, approximately [ADDRESS_307677] with an AE for the given incidence rate (θ) 
and number of subjects completing Part  B. The probabilities were  calculated by [CONTACT_7702] a 
binomial distribution for the number of AEs using SAS®. 
Protocol VX20 -445-111, Version  3.[ADDRESS_307678] With an AE in the Study if the 
AE Incidence ( ) is 5% and 10%  
Number of  Subjects 
Completing Part  B  = 5%   = 10%  
56 94.3%  99.7%  
63 96.1%  99.9%  
: incidence; AE: adverse event  
12.2 Analysis Sets  
Assignment of subjects to analysis sets will be done before the clinical data lock for the study. 
The following analysis sets will be  defined separately for Part A and Part B.  
All Subjects Set  
The All Subjects Set will include all subjects who are enrolled (defined as subjects having data in 
the clinical database) or received at least [ADDRESS_307679] data listings and disposition summary tables, unless otherwise specified.  
Full Analysis Set (FAS)  
The FAS  will include all subjects who are enrolled (defined as subjects having data in the 
clinical database) and carry the intended CFTR  allele mutation and received at least [ADDRESS_307680] data listings.  
Continuous variables  will be summarized using the fo llowing descriptive summary statistics: 
number of subjects (n), mean, SD, median, minimum value (min), and maximum value (max). 
The precision of the measurement for each continuous variable will be specified in the SAP.  
Categorical variables  will be summar ized using counts and percentages. Percentages will be 
presented to [ADDRESS_307681].  
Treatment -emergent (TE) period  for Parts A and B will include the time from the first dose of 
study drug in the respective Part through [ADDRESS_307682] dose, or the  completion of study 
participation date (Section  9.1.6 ), whichever is earlier . 
Baseline  value, unless specified otherwise, will be defined as the most recent non -missing 
measurement (scheduled or unscheduled) collected before the first dose of study drug. Details 
will be provided in SAP.  
Absolute change  from baseline  will be calculated as po st-baseline value  – baseline value.  
Protocol VX20 -445-111, Version  3.[ADDRESS_307683] disposition, demographic and baseline characteristics, prior and concomitant 
medications, study drug exposure, compliance (Part  B only), and other background 
characteristics will be sum marized for Part  A and Part  B. 
12.3.3  Efficacy and Pharmacodynamic Analysis  
Two of the secondary objectives for Part  B are to evaluate the efficacy and PD of 
ELX/TEZ/IVA. Principal features of the efficacy and PD analyses are presented in this section. 
Further de tails will be provided in the SAP.  
[IP_ADDRESS]  Analysis of Primary Efficacy Endpoints  
Not applicable as efficacy is not a primary endpoint.  
[IP_ADDRESS]  Analysis of Secondary Efficacy and Pharmacodynamic Endpoints  
A summary of observed values and change from baseline will be provi ded for all secondary 
efficacy endpoints based on the FAS in Part B.  
• Absolute change in SwCl from baseline through Week 24  
Absolute change from baseline in SwCl will be analyzed using a mixed -effects model for 
repeated measures (MMRM) approach based on the  FAS. The MMRM will be used to 
estimate the mean absolute change in SwCl through Week  24. The model will include 
absolute change from baseline in SwCl as the dependent variable, and with visit, baseline 
SwCl value, and genotype group as covariates. Data ob tained from Week  4, Week 12, and 
Week  [ADDRESS_307684] through 
Week  24. The estimated mean change from baseline in SwCl through Week  24, along with 
the corresponding 95% CI and [ADDRESS_307685]-baseline visit, obtained from the model, will be provided as well.  
• Absolute change in LCI 2.5 from baseline through Week  24 
Analysis of this endpoint will be based on an MMRM model that is similar to the analysis of 
absolute change from basel ine in SwCl through Week  24, with the baseline LCI 2.5 value 
included as a covariate instead of baseline SwCl.  
[IP_ADDRESS]  Multiplicity Adjustment  
No multiplicity adjustment is planned.  

Protocol VX20 -445-111, Version  3.0 Page 54 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  12.3.4  Safety Analysis  
Safety is a secondary objective of Part A, and the primary objective of Part  B. All safety analyses 
will be conducted for the Safety Set in Part  A and Part  B separately. The safety profile of study 
drug will be assessed based on the following safety and tolerability endpoints:  
• Treatment -emergent adverse events (TEAEs)  
• Clinical laboratory values (i.e., hematology, serum chemistry, coagulation, and uri nalysis as 
applicable)  
• Standard 12 -lead ECGs  
• Vital signs  
• Pulse oximetry  
[IP_ADDRESS]  Adverse Events  
For analysis purposes, AEs  will be classified as pretreatment AEs, TEAEs, or post -treatment 
AEs, defined as follows:  
• Pretreatment AE : any AE  that occurred before the first dose of study drug  
• TEAE : any AE that is worsened (either in severity or seriousness) or newly developed at or 
after the first dose of study drug through the end of the TE Period  
• Post-treatment AE : any AE  that worsened (either in severity or seriousness) or newly 
developed after the TE Period  
For AEs with missing or partial start dates, if there is no clear evidence that the AEs started 
before or after study drug treatment, then the AEs will be classified as TEAEs.  
AE summary tables will be presented for TEAEs only, and will include the following:  
• All TEAEs  
• TEAEs by [CONTACT_155429]  
• TEAEs by [CONTACT_764]  
• TEAEs leading to treatment discontinuation  
• TEAEs leading to treatment interruption  

Protocol VX20 -445-111, Version  3.0 Page 55 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  • Serious TEA Es 
• TEAEs leading to death  
• Grade 3 and Grade 4 TEAEs (Section  [IP_ADDRESS] ) 
Summaries will be presented by [CONTACT_252868] f requency counts 
and percentages (i.e.,  number and percentage of subjects with an event). When summarizing the 
number and percentage of subjects with an event, subjects with multiple occurrences of the same 
AE or a continuing AE will be counted once, only t he maximum severity level will be presented 
in the severity summaries, and the strongest relationship level in the relationship summaries. An 
AE overview table will be provided. In addition, a listing containing individual subject level AE 
data for all dea ths and other serious and significant AEs will be provided separately. All AEs, 
including pre - and post -treatment AEs, will be presented in individual subject data listings.  
[IP_ADDRESS]  Clinical Laboratory Assessments  
For the treatment -emergent laboratory measurements , the observed values and change from 
baseline values of the continuous hematology, serum chemistry, and coagulation results will be 
summarized in SI units at each scheduled visit.  
The number and percentage of subjects meeting a threshold analysis criterio n during the TE 
Period will be summarized. The threshold analysis criterion shift from baseline will also be 
summarized for select laboratory parameters. The threshold analysis criteria and the parameter 
selection criteria will be provided in the SAP.  
Resu lts of urinalysis will be listed in individual subject data listings only. In addition, a listing 
containing individual subject hematology, chemistry, and coagulation values outside the 
reference ranges will be provided. This listing will include data from  scheduled and unscheduled 
visits.  
[IP_ADDRESS]  Electrocardiogram  
For the treatment -emergent ECG measurements, a summary of observed values and change from 
baseline values will be provided, at each scheduled visit and time point, as applicable, for the 
following ECG interval measurements (in msec): RR, PR, QT, and QT interval corrected by 
[CONTACT_252860]’s formula (QTcF), QRS duration, and heart rate (HR) (beats per minute).  
The number and percentage of subjects meeting a threshold analysis criterion during the TE 
Period w ill be summarized. The threshold analysis criteria will be provided in the SAP.  
[IP_ADDRESS]  Vital Signs  
For the treatment -emergent vital signs measurements, the observed values and change from 
baseline values will be summarized at each scheduled visit. The following v ital signs parameters 
will be summarized: systolic and diastolic blood pressure (mm  Hg), body temperature ( C), pulse 
rate (heart rate, beats per minute), and respi[INVESTIGATOR_697] (breaths  per minute).  
The number and percentage of subjects meeting a threshold analysis criterion during the TE 
Period will be summarized. The threshold analysis criteria will be provided in the SAP.  
Protocol VX20 -445-111, Version  3.0 Page 56 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  [IP_ADDRESS]  Pulse Oximetry  
For the treatment -emergent pulse oximetry measurements, a summary of observed values and 
change from baseline values wil l be provided at each scheduled visit for the percent of oxygen 
saturation by [CONTACT_406].  
The number and percentage of subjects with shift changes from baseline (normal/missing and 
low according to the reference range) to the lowest percent of oxygen saturation during the TE 
Period will be summarized.  
[IP_ADDRESS]  Ophthalmologic Examinations  
The ophthalmolo gic examination results will be presented in individual subject data listings.  
[IP_ADDRESS]  Physical Examination  
PE findings will be presented in an individual subject data listing only.  
12.4 Interim Analysis  
Not applicable . 
12.5 Data Monitoring Committee Analysis  
The DMC (Secti on 9.1.7 ) will conduct periodic planned safety review(s) of study data. Details of 
the safety and efficacy review(s) will be described in the DMC Cha rter. 
12.6 Clinical Pharmacology Analysis  
12.6.1  Pharmacokinetic Analysis  
The PK analysis of ELX, TEZ, IVA, and relevant metabolites may be performed using nonlinear 
mixed effects modeling and/or standard noncompartmental analysis, as data allow. Metabolites 
may be in cluded in the analyses as supported by [CONTACT_33653]. Descriptive statistics will be used to 
summarize PK parameter values for all analytes.  
A detailed description of the planned PK analysis will be presented in the CPAP.  
12.6.2  Pharmacokinetic/Pharmacodynamic Analyses  
PK/PD analyses may be performed on selected PD assessments, which include SwCl, LCI 2.5, as 
well as other endpoints such as  
A sequential approach will be used to perform the population PK/PD analysis. The Bayesian 
estimates of individual PK parameters from the final population PK model will be used to 
simulate PK profiles for each subject. The simulated ELX, TEZ, IVA, or metabolite plasma 
concentrations will be used in the potential pharmacological response models to describe 
changes in ea ch endpoint. Fixed - and random -effect parameter estimates and their uncertainty 
will be estimated.  

Protocol VX20 -445-111, Version  3.0 Page 57 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  13 PROCEDURAL, ETHICAL,  REGULATORY, AND ADM INISTRATIVE 
CONSIDERATIONS  
13.1 Adverse Event and Serious Adverse Event Documentation, Severity 
Grading, and Reporting  
13.1.1  Adverse Events  
[IP_ADDRESS]  Definition of an Adverse Event  
An AE is defined as any untoward medical occurrence in a subject during the study; the event 
does not necessarily have a causal relationship with the treatment. This includes any newly 
occurring event or worsening  of a pre -existing condition (e.g.,  increase in its severity or 
frequency) after the ICF is signed.  
An AE is considered serious if it meets the definition in Section  [IP_ADDRESS] . 
[IP_ADDRESS]  Clinically Significant Assessments  
Study assessments including laboratory tests, ECGs, PEs, and vital signs will be assessed and 
those deemed to have clinically significant worsening from baseline will be documented as an 
AE. Wh en possible, a clinical diagnosis for the study assessment will be provided, rather than the 
abnormal test result alone (e.g.,  urinary tract infection, anemia). In the absence of a diagnosis, 
the abnormal study assessment itself will be listed as the AE (e .g., bacteria in urine or decreased 
hemoglobin).  
An abnormal study assessment is considered clinically significant if the subject has 1  or more of 
the following:  
• Concomitant signs or symptoms related to the abnormal study assessment  
• Further diagnostic test ing or medical/surgical intervention  
• A change in the dose of study drug or discontinuation from the study  
Repeat testing to determine whether the result is abnormal, in the absence of any of the above 
criteria, does not necessarily meet clinically significant criteria. The determination of whether the 
study assessment results are clinically significant will be made by [CONTACT_093].  
A laboratory value that is Grade [ADDRESS_307686]’s clinical status indicates a life -threatening AE.  
[IP_ADDRESS]  Documentation of Adverse Events  
All AEs will be collected from the time the ICF is signed until the following times:  
• For subjects who do not enroll: until time of screen failure (e.g.,  screen fa ilure, withdrawal of 
consent)  
• For enrolled subjects who have a Safety Follow -up Visit: through the Safety Follow -up Visit  
• For enrolled subjects who do not have a Safety Follow -up Visit, the earliest of  
o [ADDRESS_307687] dose of study drug 
(see Section  9.1.4 ) 
Protocol VX20 -445-111, Version  3.0 Page 58 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  All subjects’ parents or legal guardians will be queried, using nonleading questions, about the 
occurrence of AEs at each study visit. When possible, a constellation of signs and/or symptoms 
will be identified as [ADDRESS_307688]’s source documents. The following data will be 
documented for each AE:  
• Description of the event  
• Classification of “serious” or “nonserious ” 
• Date of first occurrence and date of resolution (if applicable)  
• Severity  
• Causal relationship to study drug(s)  
• Action taken  
• Outcome  
• Concomitant medication or other treatment given  
[IP_ADDRESS]  Adverse Event Severity  
The investigator will determine and record the sever ity of all serious and nonserious AEs. The 
guidance available at the following website will be consulted: Common Terminology 
Criteria  for Adverse Events (CTCAE), Version  5.0, Cancer Therapy Evaluation Program, 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  (Accessed 
September 2019 ). When considering the severity of an AE in a pediatric subject, the investigator 
will consider that reference ranges for pediatric clinical laboratory parameters may differ from 
those in the CTCAE. The severity of an AE described by a term that does not appear in the 
CTCAE will be determined according to the definitions in Table  13-1. 
Table  13-1 Grading of AE Severity  
Classification  Description  
Grade  1 (Mild)  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated  
Grade  2 (Moderate)  Moderate; minimal, local, or noninvasive intervention indicated; limiting age -
appropriate instrumental ADLa 
Grade  3 (Severe)  Severe or medically significant but not immediately life-threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting 
self-care ADLb 
Grade  4 (Life -threatening)  Life-threatening consequences; urgent intervention indicated   
Grade  5 (Death)  Death related to adverse event  
Source: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  (Accessed September 2019)  
ADL: activities of daily living; AE: adverse event  
Note:  A semi -colon indicates ‘or’ within the description of the grade.  
a Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, managing 
money, etc.  
b Self-care ADL refer to bathing, dressing and undressing, feeding s elf, using the toilet, taking medications, 
and not bedridden.  
Protocol VX20 -445-111, Version  3.0 Page 59 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  [IP_ADDRESS]  Adverse Event  Causality  
Every effort will be made by [CONTACT_63398], if any, to the 
study drug(s). Causality will be classified using the categories in Table  13-2. 
Table  13-[ADDRESS_307689] been ruled out, 
and/or the ev ent reappeared on re -exposure to the investigational study drug.  
Possibly related  There is an association between the event and the administration of the 
investigational study drug and there is a plausible mechanism for the event to be 
related to investig ational study drug, but there may also be alternative etiology, 
such as characteristics of the subject’s clinical status or underlying disease.  
Unlikely related  The event is unlikely to be related to the investigational study drug and likely to be 
related to factors other than investigational study drug.  
Not related  The event is related to an etiology other than the investigational study drug (the 
alternative et iology will be documented in the subject’s medical record).  
 
[IP_ADDRESS]  Study Drug Action Taken  
The investigator will classify the study drug action taken with regard to the AE. The action taken 
will be classified according to the categories in Table  13-3. 
Table  13-[ADDRESS_307690] to an AE  
Classificationa Definition  
Dose not changed  Study drug dose not changed in response to an AE  
Dose reduced  Study drug dose reduced in response to an AE  
Drug interrupted  Study drug administration interrupted in response to an AE  
Drug withdrawn  Study drug administration permanently discontinued in response to an AE  
Not applicable  Action taken regarding study drug administration does not apply.  
“Not applicable” will be used in circumstances such as when the investigational 
treatment had been completed before the AE began and no oppor tunity to decide 
whether to continue, interrupt, or withdraw treatment is possible.  
a Refer to Sections  9.7 and 9.8 for directions regarding what drug actions are permitted per protocol. 
[IP_ADDRESS]  Adverse Event Outcome  
An AE will be followed until the investigator has determined and provided the final outcome. 
The outcome will be classified according to the categories in Table  13-4. 
Table  13-4 Classifications for Outcome of an AE  
Classification  Definition  
Recovered/resolved  Resolution of an AE with no residual signs or sy mptoms  
Recovered/resolved with 
sequelae  Resolution of an AE with residual signs or symptoms  
Not recovered/not 
resolved (continuing)  Either incomplete improvement or no improvement of an AE, such that it remains 
ongoing  
Protocol VX20 -445-111, Version  3.0 Page 60 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  Table  13-4 Classifications for Outcome of an AE  
Classification  Definition  
Fatal  Outcome of an AE is death. “Fatal” will be used when death is at least possibly 
related to the AE.  
Unknown  Outcome of an AE is not known (e.g.,  a subject lost to follow -up) 
 
[IP_ADDRESS]  Treatment Given  
The investigator ensures adequate medical care is provided to subjects for any AEs, including 
clinically significant laboratory values related to study drug. In addition, the investigator will 
describe whether any treatment was given for the AE. “Yes” is used if any treatment was given 
in response to an AE, and may include treatments such  as other medications, surgery, or physical 
therapy. “No” indicates the absence of any kind of treatment for an AE.  
13.1.2  Serious Adverse Events  
[IP_ADDRESS]  Definition of a Serious Adverse Event  
An SAE is any AE that meets any of the following outcomes:  
• Fatal (death, regard less of cause, that occurs during participation in the study or occurs after 
participation and is suspected of being a delayed toxicity due to administration of the study 
drug)  
• Life-threatening, such that the subject was at immediate risk of death from the  reaction as it 
occurred  
• Inpatient hospi[INVESTIGATOR_318]  
• Persistent or significant disability/incapacity (disability is defined as a substantial disruption 
of a person’s ability to conduct normal life functions)  
• Congenital anom aly or birth defect  
• Important medical event that, based upon appropriate medical judgment, may jeopardize the 
subject or may require medical or surgical intervention to prevent  1 of the outcomes listed 
above (e.g.,  an allergic bronchospasm requiring intens ive treatment in an emergency room or 
at home)  
If a subject has a hospi[INVESTIGATOR_29918] (e.g.,  surgery) for an event or condition that 
occurred before the subject signed the ICF, and the hospi[INVESTIGATOR_252857], the hospi[INVESTIGATOR_168788], unless an AE caused the hospi[INVESTIGATOR_94252]. In addition, hospi[INVESTIGATOR_252858] n ot 
associated with an AE (e.g.,  social hospi[INVESTIGATOR_8933]) will not be 
considered to indicate an SAE.  
Clarification will be made between the terms “serious” and “severe” because they are not 
synonymous. The term “severe” is often used to describe the intensity (severity) of a specific 
event, as in mild, moderate, or severe myocardial infarction. The event itself, however, may be 
of relatively minor medical significance, such as a severe headache. This is not the same as 
Protocol VX20 -445-111, Version  3.0 Page 61 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  “serious”, which is based on subject/event outcome or action described above, and is usually 
associated with events that pose a threat to a subject’s life or functioning. Seriousness, not 
severity, serves as a guide for defining expedited regulatory reporting obligat ions.  
[IP_ADDRESS]  Reporting and Documentation of Serious Adverse Events  
All SAEs that occur after obtaining informed consent through the Safety Follow -up Visit, 
regardless of causality, will be reported by [CONTACT_252869] 
(GPS) within 24 hours of identification . In addition, all SAEs that occur after the Safety 
Follow -up Visit and are considered related to study drug(s) will be reported to Vertex GPS 
within 24  hours of identification . 
For SAEs that occur after obtaining informed consent  through  the Safety Follow -up Visit, the 
SAE Form will be completed for new/initial events as well as to report follow -up information on 
previously reported events. Investigators are asked to report follow -up information as soon as it 
becomes available to ensure timely reporting to health authorities.  
Please send completed SAE Forms to Vertex GPS via:  
Email:  (preferred choice)  
Fax:   
For technical issues related to submitting the form, contact [CONTACT_756]:  
SAEs that occur after the Safety Follow -up Visit and are considered related to study drug(s)  will 
be recorded on the Vertex Clinical Trial Safety Information Collection Form (hereafter referred 
to as the “SAE Form”) using a recognized medical term or diagnosis that accurately reflects the 
event. SAEs will be assessed by [CONTACT_252870](s) and possible etiologies. On the SAE Form, relationship to study drug(s) will be assessed 
only as related (includes possibly related) or not related (includes unlikely related), and severity 
assessment will not b e required. For the purposes of study analysis, if the event has not resolved 
at the end of the study reporting period, it will be documented as ongoing. For purposes of 
regulatory safety monitoring, the investigator is required to follow the event to reso lution and 
report the outcome to Vertex using the SAE Form.  
[IP_ADDRESS]  Expedited Reporting and Investigator Safety Letters  
Vertex, as study sponsor, is responsible for reporting suspected, unexpected, serious adverse 
reactions (S[LOCATION_003]Rs) involving the study drug(s) to all regulatory authorities, IEC, and 
participating investigators in accordance with current ICH E2A Guidelines and/or local 
regulatory requirements, as applicable. In addition, Vertex, or authorized designee, will be 
responsible for the submission of safet y letters to central IECs.  
It is the responsibility of the investigator or designee to promptly notify the local IRB/IEC of all 
unexpected serious adverse drug reactions involving risk to human subjects.  
13.[ADDRESS_307691], IMP, or medical device. In addition, suspected cou nterfeit/falsified product is 
considered a product complaint.  
Product complaints are to be reported to Vertex.  
13.2.2  Ethical Considerations  
The study will be conducted in accordance with the current ICH  E6 GCP Guidelines, which are 
consistent with the ethical pr inciples founded in the Declaration of Helsinki, and in accordance 
with local applicable laws and regulations. The IRB/IEC will review all appropriate study 
documentation to safeguard the rights, safety, and well -being of the subjects. The study will be 
conducted only at sites where IRB/IEC approval has been obtained. The protocol, Investigator’s 
Brochure, sample ICF, advertisements (if applicable), written information given to the subjects 
(including diary cards), safety updates, annual progress reports, a nd any revisions to these 
documents will be provided to the IRB/IEC by [CONTACT_155432], as allowable by [CONTACT_168802].  
13.2.[ADDRESS_307692] or legal representative or guardian (if applicable), and assent will be obtained from the 
subject (if applicable), before study participation. The method of obtaining and documenting the 
informed consent and assent ( if applicable) and the contents of the consent will comply with 
current ICH  E6 GCP Guidelines and  all applicable laws and regulations and will be subject to 
approval by [CONTACT_139411].  
13.2.[ADDRESS_307693] the safety of the subjects, the scope of the investigation, 
or the scientific quality of the study (i.e.,  efficacy assessments) will require IRB/IEC notifica tion 
before implementation, except where the modification is necessary to eliminate an apparent 
immediate hazard to human subjects. Vertex will submit all protocol modifications to the 
required regulatory authorities.  
When circumstances require an immediat e departure from procedures set forth in the protocol, 
the investigator will contact [CONTACT_139412]. If possible, contact 
[CONTACT_94321]. Any departures from the protocol will 
be fully documented in the source documentation and in a protocol deviation log.  
13.2.5  Access to Records  
The investigator will make the office and/or hospi[INVESTIGATOR_168790]. The records will also be available for direct inspection, verification, and copying, as 
required by [CONTACT_774], by [CONTACT_775] 
(FDA and others). The investigat or will comply with applicable privacy and security laws for use 
and disclosure of information related to the research set forth in this protocol.  
13.2.[ADDRESS_307694] names linked to such 
numbers will be limited to the site and the study physician and will not  be disclosed to Vertex. 
As required by [CONTACT_168803], the investigator will allow Vertex and/or its representatives access to all pertinent 
medical records to allow for the verificat ion of data gathered in the CRFs/SAE Forms and the 
review of the data collection process. The FDA and regulatory authorities in other jurisdictions, 
including the IRB/IEC, may also request access to all study records, including source 
documentation, for in spection.  
For sites participating in the US, and in accordance with the Health Insurance Portability and 
Accountability Act (HIPAA) and associated regulations, an executed HIPAA authorization will 
be obtained by [CONTACT_94324] (or the legal rep resentative of the subject) before 
research activities may begin. Each HIPAA authorization will comply with all HIPAA 
requirements including authorization allowing the site access to and use of the subject’s 
personally identifiable health information, auth orization for the site to disclose such information 
to Vertex, the FDA, and other parties requiring access under the protocol, and statements as to 
the purpose for which such information may be used and for how long.  
13.2.[ADDRESS_307695] Retention  
The investigator will maintain all study records according to current ICH  E6 GCP Guidelines 
and/or applicable local regulatory requirement(s), whichever is longest, as described in the 
Clinical Trial Agreement. If the investigator withdraws from the responsibility of keepi[INVESTIGATOR_214672] e 
study records, custody will be transferred to a person willing to accept the responsibility and 
Vertex will be notified.  
13.2.8  Study Termination  
At any time, Vertex may terminate this study in its entirety or may terminate this study at any 
particular site. In  addition, for reasonable cause, either the investigators or their IRBs/IECs may 
terminate the study at their center.  
Conditions that may lead to reasonable cause and warrant termination include, but are not limited 
to: 
• Subject or investigator noncomplianc e 
• Unsatisfactory subject enrollment  
• Lack of adherence to protocol procedures  
• Lack of evaluable and/or complete data  
• Potentially unacceptable risk to study subjects  
• Decision to modify drug development plan  
• Decision by [CONTACT_252871].  
13.2.[ADDRESS_307696] scheduled visit (or scheduled contact) of the last subject.  
Protocol VX20 -445-111, Version  3.[ADDRESS_307697] will  be entered into a CRF by [CONTACT_252872] a secure, 
validated, web -based electronic data capture (EDC) application. Vertex will have read -only 
access to site -entered clinical data in the EDC application.  
Instances of missing, discrepant, or uni nterpretable data will be queried with the investigator for 
resolution. Any changes to study data will be made to the CRF and documented in an audit trail, 
which will be maintained within the clinical database.  
13.4 Monitoring  
Monitoring and auditing procedures  developed or approved by [CONTACT_168804]. On -site checking of the CRFs/SAE Forms for completeness and 
clarity, cross -checking with source documents, and clarification of administrative matters will be 
performed.  
The s tudy will be monitored by [CONTACT_139411]. Monitoring will be done by a 
representative of Vertex or designee (study site monitor), who will review the CRFs/SAE Forms 
and source documents per current ICH E6 GCP Guidelines. The study site monitor will  ensure 
that the investigation is conducted according to the protocol design and regulatory requirements.  
13.[ADDRESS_307698]. It is the investigator’s responsibility to 
ensure the accuracy, completeness, clarity, and timeli ness of the data reported in the subject’s 
CRF. Source documentation supporting the CRF data will indicate the subject’s participation in 
the study and will document the dates and details of study procedures, AEs, other observations, 
and subject status.  
The investigator, or designated representative, will complete the CRF as soon as possible after 
information is collected.  
The audit trail entry will show the user’s identification information and the date and time of any 
correction. The investigator will pro vide formal approval of all the information in the CRFs, 
including any changes made to them, to endorse the final submitted data for the subjects for 
whom the investigator is responsible.  
Vertex will retain the CRF data  and corresponding audit trails. A co py of the final archival CRF 
in the form of a compact disc (CD) or other electronic media will be placed in the investigator’s 
study  file. 
Protocol VX20 -445-111, Version  3.[ADDRESS_307699] party except to such of the investigator’s empl oyees and staff as have been made aware 
that the information is confidential and who are bound to treat it as such and to whom disclosure 
is necessary to evaluate that information. The investigator shall not use such information for any 
purpose other than determining mutual interest in performing the study and, if the parties decide 
to proceed with the study, for the purpose of conducting the study.  
The investigator understands that the information developed from this clinical study will be used 
by [CONTACT_139383] i n connection with the development of the study drug and other drugs and diagnostics, 
and therefore may be disclosed as required to other clinical investigators, business partners and 
associates, the FDA, and other government agencies. The investigator also  understands that, to 
allow for the use of the information derived from the clinical study, the investigator has the 
obligation to provide Vertex with complete test results and all data developed in the study.  
13.7 Publications and Clinical Study Report  

Protocol VX20 -445-111, Version  3.0 Page 66 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  13.7.2  Clinical Study Report  
A CSR, written in accordance with the current ICH E3 Guideline, will be submitted in 
accordance with local regulations.  

Protocol VX20 -445-111, Version  3.0 Page 68 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  17 International Committee of Medical Journal Editors (ICMJE). December 2017. 
Recommendations for the conduct, reporting, editing, and publication of scholarly work 
in medical journals. Available at: http://www.icmje.org/recommendations/ . Accessed [ADDRESS_307700] 2018.  
 
Protocol VX20 -445-111, Version  3.0 Page 69 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  APPENDIX A  Eligible MF CFTR Mutations  
“MF” mutations are a subset of minimal function mut ations that are non -responsive to IVA and 
TEZ/IVA. A mutation is considered an MF mutation if it meets at least 1 of the following 
2 criteria:  
(1) No biological plausibility of translated protein (genetic sequence predicts the complete 
absence of CFTR protein) , or 
(2) in vitro testing that supports lack of responsiveness to IVA and TEZ/IVA.  
Inclusion of MF Mutations Based on In Vitro Testing  
Mutations that were considered to be MF mutations based on in vitro testing met the following 
criteria in in vitro experiment s: 
• baseline chloride transport that was <10% of wildtype CFTR  
• an increase in chloride transport of <10% over baseline following the addition of IVA and 
TEZ/IVA in the assay  
Eligible MF Mutations  
The mutations below are detectable by [CONTACT_13247] -cleared genotypi [INVESTIGATOR_252859] (e.g., 
sequencing).  
This list does not include every eligible mutation, and investigators should contact [CONTACT_252873].  
Protocol VX20 -445-111, Version  3.[ADDRESS_307701] of Minimal Function CFTR  Mutations Eligible for VX20 -445-111 
     
Q2X  L218X  Q525X  R792X  E1104X  
S4X Q220X  G542X  E822X  W1145X  
W19X  Y275X  G550X  W882X  R1158X  
G27X  C276X  Q552X  W846X  R1162X  
Q39X  Q290X  R553X  Y849X  S1196X  
W57X  G330X  E585X  R851X  W1204X  
E60X  W401X  G673X  Q890X  L1254X  
R75X  Q414X  Q685X  S912X  S1255X  
L88X  S434X  R709X  Y913X  W1282X  
E92X  S466X  K710X  Q1042X  Q1313X  
Q98X  S489X  Q715X  W1089X  Q1330X  
Y122X  Q493X  L732X  Y1092X  E1371X  
E193X  W496X  R764X  W1098X  Q1382X  
W216X  C524X  R785X  R1102X  Q1411X  
     
185+ 1G>T  711+5G>A  1717 -8G>A  2622+1G>A  3121 -1G>A  
296+ 1G>A  712-1G>T  1717 -1G>A  2790 -1G>C 3500 -2A>G  
296+1G >T 1248+1G>A  1811+1G>C  3040G >C (G970R)  3600+2insT  
405+1G>A  1249 -1G>A  1811+1.6kbA>G  3850 -1G>A  
405+3A>C  1341+1G>A  1811[PHONE_5254]G >T  3120G>A  4005+1G>A  
406-1G>A  1525 -2A>G  1812 -1G>A  3120+1G>A  4374+1G>T  
621+1G>T  1525 -1G>A  1898+1G>A  3121 -2A>G   
711+1G>T   1898+1G>C    
     
182delT  1119delA  1782delA  2732insA  3791delC  
306insA  1138insG  1824delA  2869insG  3821delT  
365-366insT  1154insTC  1833delT  2896insAG  3876delA  
394delTT  1161delC  2043delG  2942insT  3878delG  
442delA  1213delT  2143delT  2957delT  3905insT  
444delA  1259insA  2183AA>G a 3007delG  4016insT  
457TAT>G  1288insTA  2184delA  3028delA  4021dupT  
541delC  1343delG  2184insA  3171delC  4022insT  
574delA  1471delA  2307insA  3171insC  4040delA  
663delT  1497delGG  2347delG  3271delGG  4279insA  
849delG   1548delG  2585delT  3349insT  4326delTC  
935delA  1609del CA  2594delGT  3659delC   
1078delT  1677delTA  2711delT  3737delA   
     
Protocol VX20 -445-111, Version  3.[ADDRESS_307702] of Minimal Function CFTR  Mutations Eligible for VX20 -445-111 
     
CFTRdele1  CFTRdele16 -17b 991del5  
CFTRdele2  CFTRdele17a,17b  1461ins4  
CFTRdele2,3  CFTRdele17a -18 1924del7  
CFTRdele2 -4 CFTRdele19  2055del9>A  
CFTRdele3 -10,14b -16 CFTRdele19 -21 2105 -2117del13insAGAAA  
CFTRdele4 -7 CFTRdele21  2372del8  
CFTRdele4 -11 CFTRdele22 -24 2721del11  
CFTR50kbdel  CFTRdele22,23  2991del32  
CFTRdup6b -10 124del23bp  3121 -977_3499+248del2515  
CFTRdele11  306delTAGA  3667ins4  
CFTRdele13,14a  602del14   4010del4  
CFTRdele14b -17b 852del22  4209TGTT>AA  
     
A46D  V520F  Y569D  N1303K    
G85E  A559T  L1065P    
R347P  R560T  R1066C    
L467P  R560S  L1077P    
I507del  A561E  M1101K    
     
CFTR : cystic fibrosis transmembrane conductance regulator gene  
Source:  CFTR2.org. Clinical and functional translation of CFTR. The Clinical and Functional Translation of CFTR (CFTR2), 
US Cystic Fibrosis Foundation, Johns Hopkins University, the Hospi[INVESTIGATOR_31331]. Available at: 
http://www.cftr2.org . Accessed 15  February  2016.  
a Also known as 2183delAA>G . 
Protocol VX20 -445-111, Version  3.0 Page 72 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  APPENDIX B  Eligible ELX/TEZ/IVA -Responsive CFTR Mutations  
As described in Section  8.1, in Part B, subjects with at least 1 F508del  mutation in the  CFTR  
gene  or an  ELX/TEZ/IVA -responsive CFTR  mutation  based  on in vitro data, qualify to be 
screened for the study. The list of qualifying ELX/TEZ/IVA -responsive  CFTR  mutations is 
presented below.  
CFTR  Mutations Responsive to ELX/TEZ/IVA Based on In Vitro Data  
3141del9  G126D  R334L  S549R  H939R  W1098C  
546insCTA  H139R  R334Q  G551D  S945L  F1099L  
P5L I148T  I336K  G551S  M952I  M1101K  
S13F  M152V  T338I  R553Q  M952T  I1139V  
L15P  Y161D  S341P  A554E  L967S  D1152H  
G27R  Y161S  L346P  V562I  G970D  V1153E  
R31L  L165S  R347H  Y563N  S977F  S1159F  
A46D  R170H  R347L  P574H  D979V  S1159P  
E56K  I175V  R347P  F575Y  I980K  R1162L  
E60K  G178E  A349V  G576A  L997F  V1240G  
P67L  G178R  R352Q  G576A;R668C † A1006E  G1244E  
R74Q  F191V  R352W  D579G  Y1014C  G1249R  
R74W  D192G  Q359R  E588V  F1016S  S1251N  
R74W;V201M † E193K  W361R  S589N  I1027T  S1255P  
R74W;V201M;D1270N † G194R  S364P  I601F  Y1032C  I1269N  
R74W;D1270N † G194V  E403D  D614G  T1036N  D1270N  
R75Q  H199Y  D443Y;G576A;R668C † I618T  F1052V  W1282R  
G85E  V201M  D443Y  G622D  T1053I  R1283M  
E92K  P205S  L453S  G628R  H1054D  R1283S  
Q98R  L206W  A455E  R668C  K1060T  Q1291R  
Y109N  V232D  V456A  S737F  G1061R  V1293G  
D110E  A234D  V456F  R751L  R1066H  L1324P  
D110H  Q237E  G463V  V754M  A1067T  L1335P  
E116K  Q237H  E474K  R792G  G1069R  G1349D  
R117C  R258G  G480C  I807M  R1070Q  I1366N  
R117G  M265R  S492F  E822K  R1070W  H1375P  
R117H  F311del  I502T  D836Y  F1074L  L1480P  
R117L  F311L  F508C  S912L  L1077P   
R117P  G314E  F508C;S1251N † D924N  H1085P   
A120T  L320V  S549N  R933G  H1085R   
† Complex/compound mutations where a single allele of the CFTR  gene has multiple mutations; these exist 
independent of the presence of mutations on the other allele.  
Protocol VX20 -445-111, Version  3.0 Page 74 of 74 
Vertex Pharmaceuticals Incorporated  Confidential Information  15.2 Investigator Signature [CONTACT_94333] #:  VX20 -445-111 Version #:  3.0 Version Date:  21 October 2021  
Study Title: A Phase 3 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of 
Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects [ADDRESS_307703] the study according to its 
terms. I understand that all informati on concerning elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor 
(IVA) and this protocol supplied to me by [CONTACT_139369] (Vertex) is 
confidential.  
 
 
Printed Name    
[CONTACT_155436]  
 